3 completed, 3 recruiting, 2 active not recruiting, 1 approved for marketing. 5 Phase 2, 3 Phase 3, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Recruiting 2, Active not recruiting 1, Completed 1, Terminated 1 |
| Phase 3 | 3 | Active not recruiting 1, Completed 1, Recruiting 1 |
| Not applicable | 1 | Completed 1 |
Follow IC-MPGN: new trials by email Literature Review of IC-MPGN trials Research Report on IC-MPGN
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Chinese Adults With Kidney Disease ADX-038, Telitacicept - Immunoglobulin A Nephropathy (IgAN), Complement 3 Glomerulopathy (C3G) | Phase 2 | Recruiting | ADARx Pharmaceuticals, Inc. | 30 | 2026-05-21 | 2026-09-03 |
| Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease ADX-038 Dose Level 2, ADX-038 Dose Level 1 - IgAN, C3G | Phase 2 | Recruiting | ADARx Pharmaceuticals, Inc. | 45 | 2025-08-28 | 2026-10-20 |
| A Study of SGB-9768 in Patients With Complement-mediated Kidney Diseases SGB-9768 - IgA Nephropathy (IgAN), C3 Glomerulopathy | Phase 2 | Active not recruiting | Suzhou Sanegene Bio Inc. | 45 | 2025-06-06 | 2026-09-04 |
| Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN Placebo, iptacopan - IC-MPGN | Phase 3 | Recruiting | Novartis Pharmaceuticals | 106 | 2023-10-02 | 2026-07-13 |
| An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis Pegcetacoplan - C3G, IC-MPGN | Phase 3 | Active not recruiting | Apellis Pharmaceuticals, Inc. | 100 | 2023-05-29 | 2026-04-02 |
| Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis Pegcetacoplan, Placebo - C3G, IC-MPGN | Phase 3 | Completed | Apellis Pharmaceuticals, Inc. | 124 | 2021-11-12 | 2026-01-29 |
| Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN Pegcetacoplan - C3G, IC-MPGN | Phase 2 | Completed | Apellis Pharmaceuticals, Inc. | 13 | 2021-09-07 | 2026-04-21 |
| Non-contrast Enhanced MRI in Patients With C3 Glomerulopathy (C3G) or Immune-complex Membranoproliferative Glomerulonephritis (IC-MPGN) Enrolled in the ACH471-205 Study Non contrast-enhanced magnetic resonance imaging - C3 Glomerulonephritis, C3 Glomerulopathy | Not applicable | Completed | Mario Negri Institute for Pharmacological Research | 7 | 2018-12-06 | 2021-11-26 |
| A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471 Danicopan - C3 Glomerulonephritis, C3 Glomerulopathy | Phase 2 | Terminated | Alexion Pharmaceuticals, Inc. | 22 | 2018-06-20 | 2023-08-21 |
| C3G/Primary IC-MPGN EAP Pegcetacoplan - C3G, IC-MPGN | Approved for marketing | Apellis Pharmaceuticals, Inc. | 2025-11-06 |
Glomerulonephritis, Membranoproliferative (7) · Glomerulonephritis, IGA (3) · Proteinuria (1)
Female Urogenital Diseases (10) · Female Urogenital Diseases and Pregnancy Complications (10) · Male Urogenital Diseases (10) · Urogenital Diseases (10) · Urologic Diseases (10) · Glomerulonephritis (9) · Immune System Diseases (9) · Kidney Diseases (9) · Nephritis (9) · Autoimmune Diseases (3) · Pathological Conditions, Signs and Symptoms (1) · Signs and Symptoms (1) · Urination Disorders (1) · Urological Manifestations (1)
pegcetacoplan (4) · danicopan (1) · iptacopan (1) · telitacicept (1)
Apellis Pharmaceuticals, Inc. (4) · ADARx Pharmaceuticals, Inc. (2) · Alexion Pharmaceuticals, Inc. (1) · Mario Negri Institute for Pharmacological Research (1) · Novartis Pharmaceuticals (1) · Suzhou Sanegene Bio Inc. (1)
Italy (7) · United States (6) · Australia (5) · Netherlands (5) · Spain (5) · United Kingdom (5) · Argentina (4) · Brazil (4) · France (4) · South Korea (4) · Switzerland (4) · Belgium (3) · Czechia (3) · Israel (3) · Japan (3)
Arezoo Mirad (1) · Arezoo Mirad, MD (1)
PMID 42133432, PMID 36423588, PMID 37926085, PMID 41337715
2017 (1), 2023 (1)